ViiV Healthcare Named Axmed as HIV Medicine Distributor
The partnership expands supply chain access for healthcare procurers operating in more than 50 middle-income countries.
Updated on Oct. 12, 2026 in Healthcare
Live Poll
Do you trust that private partnerships will successfully expand medicine access for patients in middle-income nations?
ViiV Healthcare has appointed the technology-enabled platform Axmed as a non-exclusive distributor for its HIV medicines. This agreement aims to streamline procurement and logistics for healthcare institutions across more than 50 middle-income nations.
Why it matters
Middle-income nations often face unique pharmaceutical access challenges because they do not qualify for the lower-income procurement mechanisms available to poorer regions. This shift uses a B2B platform to lower procurement costs and manage the supply chain gap.
The distribution partnership spans more than 50 middle-income countries, marking a targeted effort to service these specific markets. The exact value of the distribution deal was not disclosed.
The players
ViiV Healthcare
A specialist pharmaceutical company focused on HIV treatment that was established in 2009 by shareholders GSK and Shionogi.
Axmed
A technology-enabled business-to-business platform provider that facilitates medicine procurement and supply chain logistics.
The details
Axmed operates a technology-enabled B2B platform that directly connects healthcare procurers with pharmaceutical suppliers. By digitizing the procurement process, the platform aims to reduce overhead costs and simplify logistical coordination for local institutions. This non-exclusive appointment allows ViiV Healthcare to utilize existing digital infrastructure to reach markets that previously lacked efficient access channels.
Timeline
November 2009: ViiV Healthcare was established.
October 12, 2026: ViiV Healthcare and Axmed announced their distribution partnership.
Market Landscape
This partnership addresses the 'middle-income trap' in pharmaceutical access, where countries are often ineligible for the lower-income pricing tiers established by the Global Access Mechanism. It signals a move toward using specialized digital B2B platforms to solve long-standing logistical hurdles.
Operators in middle-income markets should monitor whether this B2B platform model reduces local acquisition costs or supply delays for essential medicines. Procurement managers in these regions should review if their current supply chain partners offer similar digital integration capabilities.
The takeaway
This partnership demonstrates a growing reliance on digital B2B platforms to solve last-mile access issues in complex pharmaceutical markets. Procurement leaders should evaluate their current supply chain tech stack against the efficiency benchmarks provided by modern, technology-enabled platforms.
Further reading
For more on industry shifts in medical supply, visit the Healthcare section.
More information
Find additional details on the company at the ViiV Healthcare company information portal.
Source note: This article includes information reported by Scientist Live.
Live Poll
Do you trust that private partnerships will successfully expand medicine access for patients in middle-income nations?
